Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Treat Rev. 2014 Jun;40(5):648-55. doi: 10.1016/j.ctrv.2013.10.003. Epub 2013 Oct 23.

Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.

Author information

  • 1Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy.
  • 2Department of Oncology, University of Torino, Candiolo, Torino, Italy; IRCC Institute for Cancer Research and Treatment, Candiolo, Torino, Italy; FIRC Institute of Molecular Oncology (IFOM), Milano, Italy.
  • 3Division of Gynecologic Oncology, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy.
  • 4Breast Cancer Program Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy.
  • 5Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy. Electronic address: giuseppe.curigliano@ieo.it.

Abstract

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence. This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.

Copyright © 2013 Elsevier Ltd. All rights reserved.

KEYWORDS:

Breast cancer; Cell free DNA; Circulating nucleic acids; Colorectal cancer; Lung cancer; Ovarian cancer; Plasma/serum DNA; Prostate cancer

PMID:
24184333
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk